Eric Lefkofsky is Creating the Clinical Study Singularity

Eric Lefkofsky is one of the biggest names in medical philanthropy throughout the United States. Having donated tens of millions of dollars to cancer research alone, the entrepreneur has become one of the most appreciated philanthropists of his age. But unlike many independently wealthy philanthropists, Lefkofsky likes to take a more hands-on approach to his largesse. In 2016, Lefkofsky founded a company, Tempus, which seeks to revolutionize the way in which cancer is treated through putting the most powerful information available into the hands of oncologists.

After a close family member was diagnosed with cancer, Lefkofsky was dismayed to discover that many oncologists working in the field today have less access to vital information than the typical truck driver. This disturbing realization prompted Lefkofsky to begin looking into ways in which better sources of data and analytic intelligence can be put into the hands of treating physicians in real-time. He eventually came to the conclusion that such new technologies as CRISPR and human gene sequencing were not being used to anywhere near their full potential. These new technologies were a potential treasure trove of data that could be used by oncologists in real time to formulate far more effective treatment protocols for each of their patients and learn more about Eric.

Eventually, the idea for Tempus began coalescing in Lefkofsky’s head. It would be a means to effectively allow oncologists to answer the same questions, even with complex data sets, that would have previously only been possible to effectively answer through the use of large-scale clinical studies. Even a decade ago, such a platform would have been impossible to create. But today, through the use of such means as artificial intelligence and the vast computing power contained in the cloud, it is possible to sift through mind-boggling volumes of data, teasing out the subtle patterns and correlations that exist between seemingly unrelated factors and more information click here.

Lefkofsky believes that this new technology will effectively enable physicians to gain a near-infinite granularity in their understanding of how patients react to medicines and treatments. It will eventually allow doctors to custom design treatment protocols to each individual patient.

More Visit: https://www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html

Oncotarget’s E-Cigarette Study

A study has been conducted by medicine man Ifran Rahman that has shed light on the unfortunate notion that e-cigarettes much like regular cigarettes are hazardous to health. Specifically it has been identified that the vapors release inflammatory proteins that are hazardous to gum tissue at a molecular level. In addition to this, the coupled flavor vapors are also hazardous to the gum tissue. When vapors are burned, the damage occurs. This is unfortunate mostly in that many people have the opinion that e-cigs are a healthy substitute to regular cigarettes when in fact it has become quite clear that they are not. Though they affect health in different ways, users are risking their well being by using either of them. They both also contain nicotine which is both addictive and another hazard that could lead to several oral diseases. Check the journal at SCImago Journal & Country Rank.

Ifran Rahman hopes that e-cig companies will start to release all the ingredients of their products to full public view so that he may uncover more possible secrets of the e-cig companies. Up to this point it seems that the companies have not been fully honest in documenting the ingredients required to produce such hazardous products. The goal of the studies conducted by Ifran Rahman are simply to educate the public more adequately on the effects of using such products being that they have been a bit ignorant to the facts up to this point. Not to the public’s discredit. As Ifran Rahman continues to study the products he hopes the companies will be more willing to share private information and better educate the public on what it is that they’re unknowingly consuming.

Oncotarget is a detailing of pathological routes of diseases, cancer studies, therapy studies, and patient management studies all coupled together in a peer to peer review. The efforts of such collections is to produce better practices in the medical industry via improved patient care as well as development of more effective treatments and management programs. The trialed evidence also goes over the effectiveness of treatments by practicing medical professionals. Visit Oncotarget’s profile page at facebook.com